Select Page

PLANO, TX — November 2, 2020. Axenic™ Health Solutions Inc., a U.S-based provider of innovative infection prevention solutions, is proud today to announce its acquisition of substantially all assets and intellectual property formerly owned by the U.K-based entities, Q Surgical Technologies, Ltd. And Q Biotechnologies, Ltd.

These acquisitions will allow Axenic to both globally expand and rapidly diversify an existing portfolio of infection prevention products originally designed for the defense and healthcare industries, and currently distributed to markets across EMEA, the United States and Asia under the brand name, Q Shield™.  Following today’s announcement, Axenic will accelerate its plans to develop additional patentable hand and surface protectants to serve commercial in any industry, governments, nonprofits, and consumers anywhere in the world.

Additionally, as part of its global expansion strategy, Axenic plans to launch a suite of software-based subscription services to provide customers environment monitoring and pathogen exposure analysis so that they may better protect their properties, and people, in real time.

“Acquiring the intellectual property of Q Surgical and Q Biotechnologies, positions Axenic to deliver our transformative products to any market or region at a time when managing pathogen exposure, and the devastating costs associated with such risks, have become critical for every person, every business and every economy around the world,” says Axenic Co-Founder and Chief Executive Officer, Todd Evans. “In addition to our commercial expansion prioritizing healthcare, education and first responders, Axenic will leverage our new assets and technologies into customized formulations to serve the urgent recovery needs of the hospitality, transportation and entertainment industries. In this way, Axenic seeks to advance the state-of-the-art for hygiene protection everywhere.”

Through Axenic’s patent pending multi-SiQuat technology, Q Shield™ products offer durable defense to hands and surfaces against contamination from a broad spectrum of pathogens currently unmatched by competitors in the market. In independent tests conducted at a biosafety level three laboratory (BSL-3) accredited by the College of American Pathologists (CAP), Q-Shield’s non-toxic solutions demonstrated definitive and durable effect against pervasive and lethal pathogens, including SARS-CoV-2, the specific coronavirus associated with the disease COVID-19.

“There is no question in my mind that this collaboration of our scientific discovery with Axenic’s commercial know how can create a global market leader in infection prevention, at time when it is needed probably more than ever before,” says Andrew Kemp, inventor and Co-Founder of Q Surgical Technologies, Ltd. And Q Biotechnologies Ltd.

“Q Shield™ fills a crucial need in the efforts to minimize the incidence of devastating hospital acquired infections,” says Shalom Z. Hirschman, M.D., an infectious disease expert and Medical Advisor at Axenic Health Solutions, Inc. Dr. Hirschman is a founding faculty member and former Director of the Division of Infectious Diseases at renowned Mount Sinai School of Medicine (now the Icahn School of Medicine) in New York City. “Furthermore,” adds Dr. Hirschman, “recent data showing that SARS-CoV-2 is a robust virus that can survive for 28 days on some surfaces, presents another crucial need for the unique prolonged surface protection properties of Q Shield™ products.”

Consumers strained by the hardship of living through a pandemic are responding enthusiastically to news of Axenic’s planned expansion for Q Shield products:

“Since the start of COVID, necessary acts of daily life have become much harder and take longer to do. I’m always trying to decide, ‘do I drive home from the grocery store with the gloves on, or take them off and sanitize my hands, steering wheel, door handles or anything else I might have touched along the way?” says Diane Provo, M.S. Ed., a teacher and education consultant based in Marin County, CA. “Discovering Q-Shield changed my life dramatically. I could now eliminate the glove-wearing and all the sanitizing procedures I was doing to keep my hands safe from transmission. Most of all, Q Shield eliminated my constant fear of touching a surface. It gave me a piece of much-needed normalcy, and where there is normalcy, there is hope.”

Terms of the acquisition were not disclosed. With these transactions, Axenic™ assumes full responsibility for the manufacture of all Q Shield™ products and services. Axenic will seek to distribute its full suite of offerings through enterprise, retail, and direct-to-consumer channels.

ABOUT Q Surgical Technologies and Q Biotechnologies Ltd:

Q Biotechnologies, Ltd researches, develops, manufactures and distributes products for infection prevention, under exclusive license. Q Biotechnologies trades worldwide and its products have been used in a multitude of industries. Its portfolio includes rapid and accurate surface testing, persistent surface agents that deliver pathogen protection, hand hygiene disinfectants and capital equipment. Q Surgical Technologies, Ltd, is a holding company responsible for the intellectual property and patents related to Q Biotechnologies and its activities.

ABOUT Axenic™ Health Solutions, Inc.: Axenic™ Health Solutions Inc., seeks to transform the standards of commercial and consumer hygiene, globally, by delivering its Q Shield™-branded infection-prevention products to businesses, governments, non-profits and individuals in any environment, anywhere in the world. Through Axenic’s innovative and patent pending multi-SiQuat technology, Q Shield™ products offer durable defense to hands and surfaces against a broad spectrum of pathogens unmatched by competitors in the market. Axenic is also developing a suite of software-based subscription services to deliver environment monitoring and pathogen exposure analysis so that clients may better-protect of their properties, and people, in real time. Axenic is headquartered in Plano, TX with research and development offices in Lincoln, United Kingdom. To learn more, visit:

Media contact:
Wendy Lane Stevens, Managing Partner, FINN Partners
T: +1 503 546 7900 M: +1 503 490 2904 E: